The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.
US FDA grants tentative nod to Dr Reddy's twice-yearly HIV prevention drug
BU
Business Standard - LatestBy Anjali Singh
EXECUTIVE SUMMARY
The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.
Key Takeaways
- US FDA grants tentative nod to Dr Reddy's twice-yearly HIV prevention drug.
- The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.
- The tentative approval for generic lenacapavir is expected to accelerate affordable access to the twice-yearly HIV prevention injection across 120 countries outside the US.
Read Complete Original Article
Published originally on Business Standard - Latest
